Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Chinese CRO Pharmaron acquires U.K.-based Quotient Bioresearch

Beijing, China-based contract research organization Pharmaron has snapped up fellow CRO Quotient Bioresearch as it looks to broaden its reach both technically and geographically.

Qualicaps gets Latin American foothold with acquisition of Brazil's Genix

Capsulemaker Qualicaps is adding another country, and another continent, to its manufacturing network. It has secured a spot in Brazil with the acquisition of a capsulemaker there.

Plant to manufacture yellow fever jab slated for Dakar

Some drugmakers are expanding production in Africa to take advantage of a growing number of countries where rising incomes and national healthcare can pay for new meds. Now, through a number of sources of financing, a new plant will be built to manufacture yellow fever vaccine, a protection that has been in short supply.

J&J partners with San Diego startup Cue to develop portable HIV viral load Dx

Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.

China's BeiGene pitches a $150M IPO to fund its cancer pipeline

Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $150 million to support its pipeline of targeted cancer drugs.

French startup raises $27M from Chinese investor for noninvasive ultrasound glaucoma treatment

Eye Tech Care has nabbed a commitment from China-focused investor Everpine Capital to invest about €24.8 million ($26.9 million) in two rounds. The firm has already invested an initial, undisclosed amount and it's working with the Lyon-based startup to gain a regulatory approval from the China Food and Drug Administration for its noninvasive glaucoma ultrasound treatment, which is already marketed in Europe.

OrbiMed backs China's Zai Lab in a $100M B round

Shanghai-headquartered drug developer Zai Lab said it locked up more than $100 million in Series B financing, raising cash from a syndicate including OrbiMed and Sequoia Capital.

Another Chinese biopharma lines up for a billion-dollar IPO

Chinese drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $1 billion, according to reports, joining a slew of local biopharma companies headed to the public markets.

China approves Sinovac's vaccine for hand, foot and mouth disease

In December 2015, the China FDA approved the first vaccine against the virus that causes hand, foot and mouth disease, a common infectious disease often found in children. But competition was not far behind: the agency approved a second vaccine against the virus on Monday, this one developed by Sinovac.

Report: Chinese biopharma Jiangsu Hansoh eyes a $3B IPO

Jiangsu Hansoh Pharmaceutical, a Chinese drug developer, is moving toward a Hong Kong IPO worth up to $3 billion, according to Dow Jones.